Boston Scientific stock faces slower growth after Q3 reset
Published on 10/31/2026 at 10:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSSlower growth meets pipeline progress
- Third-quarter sales rose 1.5 percent, while the company reduced parts of its 2026 outlook after an operational disruption.
- New device clearances and enrollment in the Elite AF trial support Boston Scientific's longer-term product pipeline.
Boston Scientific reported third-quarter results on Wednesday, October 28, with sales of 5.138 billion US dollars, up 1.5 percent from the year-earlier period. Adjusted earnings per share reached 0.73 US dollars, while the company lowered parts of its outlook for the remainder of 2026.
The results were carried by a broad product pipeline, but growth slowed sharply from the second quarter. The Financial Times company announcement said Boston Scientific began enrolling patients in the Elite AF clinical trial for its next-generation WATCHMAN device.
The company also received US Food and Drug Administration 510(k) clearance for the Navigator Flex ureteral access sheath, the LithoVue Elite digital flexible ureteroscope and an expanded size offering for the SEISMIQ intravascular lithotripsy catheter. These developments strengthen the product pipeline, although they do not immediately offset the weaker near-term growth outlook.
Outlook reflects operating pressure
Boston Scientific expects fourth-quarter sales to decline by as much as 3 percent year over year and guides to adjusted earnings per share of 0.77 to 0.79 US dollars. Full-year adjusted earnings per share guidance stands at 3.16 to 3.18 US dollars, below the average analyst estimate cited by the Irish Examiner.
Boston Scientific stock traded at 37.63 euros on Lang & Schwarz at 10:30:45 CET on Saturday, October 31, 2026. The real-time quote of Boston Scientific stock is available separately.
Boston Scientific Corporation
- ISIN: US1011371077
- Lang & Schwarz price: 37.63 euros on October 31, 2026 at 10:30:45 Berlin time
- Third-quarter sales: 5.138 billion US dollars
- Adjusted third-quarter earnings per share: 0.73 US dollars
US medical-device shares trade within the wider context of the S&P 500, where sector sentiment can influence valuation and risk appetite.
